Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANONICAL: Canagliflozin in HFpEF with Type 2 Diabetes
jRCTs051180030Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of canagliflozin in heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Change in body weight from baseline to week 24 and Change in BNP from baseline to week 24. Started Apr 2018; status: completed.
02
Drugs
canagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051180030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180030.